GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating ch
| Current Price | ₹2,188.30 |
|---|---|
| Market Cap | ₹37,071 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 36.6 |
| Return on Equity | 49.11% |
| 52-Week Range | ₹1,968.00 – ₹3,515.95 |
| Beta (1Y) | 0.57 |
| Dividend Yield | 2.60% |
1. Pharmaceuticals-100%
Glaxosmithkline Pharmaceuticals Ltd. is trading at ₹2,188.30, with a market capitalisation of ₹37,071 Cr.
Glaxosmithkline Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Glaxosmithkline Pharmaceuticals Ltd. has a P/E of 36.6 and a return on equity of 49.11%.